Brokerages Set AnaptysBio Inc (ANAB) Target Price at $126.60

Shares of AnaptysBio Inc (NASDAQ:ANAB) have earned an average rating of “Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $126.60.

ANAB has been the topic of several recent research reports. Cantor Fitzgerald set a $140.00 target price on AnaptysBio and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Stifel Nicolaus set a $124.00 target price on AnaptysBio and gave the stock a “buy” rating in a report on Tuesday, April 2nd. Zacks Investment Research upgraded AnaptysBio from a “sell” rating to a “buy” rating and set a $77.00 target price on the stock in a report on Wednesday, March 6th. Guggenheim initiated coverage on AnaptysBio in a report on Friday, February 22nd. They set a “buy” rating and a $135.00 target price on the stock. Finally, Wedbush restated an “outperform” rating on shares of AnaptysBio in a report on Friday, March 1st.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. FMR LLC lifted its holdings in AnaptysBio by 0.9% in the first quarter. FMR LLC now owns 4,047,987 shares of the biotechnology company’s stock valued at $295,705,000 after acquiring an additional 35,252 shares during the last quarter. Vanguard Group Inc. lifted its holdings in AnaptysBio by 20.0% in the third quarter. Vanguard Group Inc. now owns 1,851,930 shares of the biotechnology company’s stock valued at $184,767,000 after acquiring an additional 308,517 shares during the last quarter. BlackRock Inc. lifted its holdings in AnaptysBio by 11.7% in the fourth quarter. BlackRock Inc. now owns 1,816,825 shares of the biotechnology company’s stock valued at $115,894,000 after acquiring an additional 189,685 shares during the last quarter. OppenheimerFunds Inc. lifted its holdings in AnaptysBio by 0.3% in the first quarter. OppenheimerFunds Inc. now owns 1,075,890 shares of the biotechnology company’s stock valued at $78,592,000 after acquiring an additional 3,671 shares during the last quarter. Finally, Viking Global Investors LP lifted its holdings in AnaptysBio by 11.3% in the first quarter. Viking Global Investors LP now owns 830,160 shares of the biotechnology company’s stock valued at $60,643,000 after acquiring an additional 84,123 shares during the last quarter.

Shares of AnaptysBio stock traded up $2.11 on Thursday, hitting $70.66. 381,061 shares of the company were exchanged, compared to its average volume of 256,343. The stock has a market cap of $1.91 billion, a P/E ratio of -28.26 and a beta of 2.16. AnaptysBio has a 1-year low of $54.26 and a 1-year high of $110.00.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, May 7th. The biotechnology company reported ($0.82) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.83) by $0.01. As a group, research analysts forecast that AnaptysBio will post -3.63 earnings per share for the current fiscal year.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's products include Etokimab, an anti-interleukin (IL)-33 program for the treatment of atopic dermatitis, eosinophilic asthma, and chronic rhinosinusitis with nasal polyps; ANB019, an anti-IL-36 receptor program for generalized pustular psoriasis and palmo-plantar pustular psoriasis; and anti-inflammatory checkpoint modulators for inflammatory diseases.

See Also: Dividend Stocks – Are They Right For You?

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.